CAR.k.28
Phase 1Small molecule
CAR.k.28 is one of 40 small molecule programs targeting Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma
#DrugCompanyPhaseTrials
1Zydelig
GileadApproved
Jaypirca
Eli LillyPhase 3
Rituxan
RochePhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Nemtabrutinib
Merck & Co.Phase 3
Venclexta
AbbViePhase 2
Gazyva
RochePhase 2
Beqalzi
BBeOne Medicines
Phase 3
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAR.k.28. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details